Claims for Patent: 6,642,007

Summary for Patent: 6,642,007

Title:	Assays for measurement of type II collagen fragments in urine
Abstract:	This invention provides novel methods for monitoring urine for type II collagen fragment using a combination of a capture antibody and a detection antibody, such that type II collagen is distinguished from other collagen fragments.
Inventor(s):	Saltarelli; Mary J. (Mystic, CT), Johnson; Kimberly S. (Gales Ferry, CT), Otterness; Ivan G. (Groton, CT)
Assignee:	Pfizer Inc. (New York, NY)
Application Number:	09/504,262
Patent Claims:	1. A method for monitoring urine for type II collagen fragments, said method comprising: a) contacting said urine with a capture antibody, wherein said capture antibody binds specifically to type II collagen fragments, to the substantial exclusion of any binding to type I or III collagen fragments; b) contacting said urine with a detection antibody, wherein said detection antibody binds specifically to collagenase-generated collagen fragments, wherein said fragments comprise the sequences set forth in SEQ ID NO:1 or SEQ ID NO:2; and c) detecting the amount of type II collagen fragments bound to said capture and detection antibodies. 2. A method according to claim 1 wherein said capture and detection antibodies are monoclonal antibodies. 3. A method according to claim 1 wherein said detection antibody has a V.sub.H sequence at least 95% homologous to that set forth in SEQ ID NO: 32, and a V.sub.L sequence at least 95% homologous to that set forth in SEQ ID NO: 33. 4. A method according to claim 1 wherein said detection antibody has the same CDRs as the V.sub.H sequence set forth in SEQ ID NO: 32, and the same CDRs as the V.sub.L sequence set forth in SEQ ID NO: 33. 5. A method according to claim 1 wherein said capture antibody binds to the sequences set forth in SEQ ID NOS: 3 and 4. 6. A method according to claim 5 wherein said capture antibody has a V.sub.H sequence at least 95% homologous to that set forth in SEQ ID NO: 48, and a V.sub.L sequence at least 95% homologous to that set forth in SEQ ID NO: 49. 7. A method according to claim 5 wherein said capture antibody has the same CDRs as the V.sub.H sequence set forth in SEQ ID NO: 48, and the same CDRs as the V.sub.L sequence set forth in SEQ ID NO: 49. 8. A method according to claim 1 wherein said contacting steps a) and b) occur simultaneously. 9. A method according to claim 8 wherein after said contacting steps, and prior to said detecting step, said capture antibody is immobilized onto a magnetic material. 10. A method according to claim 9 wherein said capture antibody is biotinylated, and said magnetic material is a magnetic streptavidin bead. 11. A method according to claim 9 wherein prior to said detecting step a majority of unbound materials are separated from said immobilized capture antibody. 12. A method according to claim 11 wherein said immobilized capture antibodies are resuspended in a buffered solution prior to said detecting step c). 13. A method according to claim 1 wherein said contacting steps a) and b) occur sequentially. 14. A method according to claim 13 wherein after said contacting step a), and prior to said contacting step b), said capture antibody is immobilized onto a magnetic material. 15. A method according to claim 14 wherein said capture antibody is biotinylated, and said magnetic material is a magnetic streptavidin bead. 16. A method according to claim 14 wherein prior to said contacting step b) a majority of unbound materials are separated from said immobilized capture antibody. 17. A method according to claim 16 wherein said immobilized capture antibodies are resuspended in a buffered solution prior to said detecting step c). 18. A method according to claim 1 wherein said capture antibody is present in said contacting step a) at a concentration of between about 5 to about 20 .mu.g/ml. 19. A method according to claim 18 wherein said capture antibody is present in said contacting step a) at a concentration of about 10 .mu.g/ml. 20. A method according to claim 1 wherein said detection antibody is present in said contacting step b) at a concentration of between about 10 to about 30 .mu.g/ml. 21. A method according to claim 20 wherein said detection antibody is present in said contacting step b) at a concentration of about 20 .mu.g/ml. 22. A method according to claim 1 wherein said detecting step is performed by detecting the result of an enzymatic reaction, an electrochemical signal, an optical signal, a radioactive signal, a fluorescent signal or through a scintillation proximity assay (SPA). 23. A method according to claim 1 wherein said detecting step is performed by measuring electrochemiluminescence, luminescence or light emitted and read by a .beta. scintillation counter. 24. A method according to claim 1 wherein said contacting steps a) and b) are performed in a buffer comprising Tris pH 7.4 at a concentration of between 50 and 250 mM, Tween-20 at a concentration of between 0.5 and 2.0%, BSA at a concentration of between 0.5 and 2.0%, and NaCl at a concentration of between 100 and 200 mM. 25. A method according to claim 1 comprising the further steps of: d) contacting a series of control samples with said capture antibody; e) contacting said control samples with said detection antibody; and f) detecting the amount of type II collagen fragments in said control samples bound to said capture and detection antibodies. 26. A method according to claim 25 wherein said control samples comprise known amounts of type II collagen fragments diluted in control urine. 27. A method according to claim 1 comprising a further step of removing unbound detection antibody after said contacting step b) and before said detecting step c). 28. A kit for monitoring urine for type II collagen fragments, said kit comprising: a) a capture antibody, wherein said capture antibody binds specifically to type II collagen fragments, to the substantial exclusion of any binding to type I or III collagen fragments; b) a detection antibody, wherein said detection antibody binds specifically to collagenase-generated collagen fragments, wherein said fragments comprise the sequences set forth in SEQ ID NO:1 or SEQ ID NO:2; c) a container; and d) instructions describing a method of using said first antibody and said second antibody to monitor biological media for type II collagen fragments. 29. A kit according to claim 28, wherein said detection antibody has a V.sub.H sequence at least 95% homologous to that set forth in SEQ ID NO: 32, and a V.sub.L sequence at least 95% homologous to that set forth in SEQ ID NO: 33, and said capture antibody has a V.sub.H sequence at least 95% homologous to that set forth in SEQ ID NO: 48, and a V.sub.L sequence at least 95% homologous to that set forth in SEQ ID NO: 49. 30. A kit according to claim 28, wherein said detection antibody has the same CDRs as the V.sub.H sequence set forth in SEQ ID NO: 32, and the same CDRs as the V.sub.L sequence set forth in SEQ ID NO: 33, and said capture antibody has the same CDRs as the V.sub.H sequence set forth in SEQ ID NO: 48, and the same CDRs as the V.sub.L sequence set forth in SEQ ID NO: 49. 31. A kit according to claim 28, said kit further comprising: e) a positive control fluid comprising control urine containing a known amount of type II collagen fragments; and f) a dilution fluid comprising control urine for diluting samples being tested with said kit. 32. A method of diagnosing a patient for a disease state associated with the degradation of type II collagen, said method comprising the step of detecting the presence of atypically large amounts of type II collagen fragments in urine collected from said patient, wherein said fragments are detected using a detection antibody active against the sequences set forth in SEQ ID NOS: 1 and 2. 33. A method according to claim 32, wherein said disease state is osteoarthritis or rheumatoid arthritis. 34. A method of performing a clinical trial to evaluate a drug believed to be useful in treating a disease state associated with the degradation of type II collagen, said method comprising: a) measuring the level of type II collagen fragments in urine collected from a set of patients; b) administering said drug to a first subset of said patients, and a placebo to a second subset of said patients; c) repeating step a) after the administration of said drug or said placebo; and d) determining if said drug is reducing the amount of type II collagen fragments present in said urine of said first subset of patients to a degree that is statistically significant as compared to any reduction occurring in said second subset of patients, wherein a statistically significant reduction indicates that said drug is useful in treating said disease state. 35. A method according to claim 34, wherein said disease state is osteoarthritis or rheumatoid arthritis.

Details for Patent 6,642,007

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2018-11-02